Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: Results of an Austrian observational trial

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Fiegl, Michael ^a   Mlineritsch, Brigitte ^b   Hubalek, Michael ^a   Bartsch, Rupert ^c   Pluschnig, Ursula ^c   Steger, Günther G ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; DOCETAXEL; DOXORUBICIN; GEFITINIB; GEMCITABINE; LAPATINIB; NAVELBINE; PLATINUM DERIVATIVE; RALTITREXED; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; MACROGOL DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; AUSTRIAN; BREAST CANCER; CANCER REGRESSION; CANCER RISK; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COUGHING; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; ETHNIC GROUP; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART DISEASE; HORMONAL THERAPY; HUMAN; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; AUSTRIA; BREAST TUMOR; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; AUSTRIA; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; POLYETHYLENE GLYCOLS;

EID: 80052032897     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-373     Document Type: Article

References (26)

1. Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H, . Central European Cooperative Oncology Group (CECOG) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009, 20:1771-85. 10.1093/annonc/mdp261, 19608616, Central European Cooperative Oncology Group (CECOG).
2. Prassl K, Sahanic A, Reicher B, Denz H, Freund M, Fiegl M. Striking response with bevacizumab and chemotherapy in a woman with heavily pretreated breast cancer: a case presentation. Memo 2008, 1:149-51.
3. Northfelt DW, Martin FJ, Working P, Volberding PA, Russell J, Newman M, Amantea MA, Kaplan LD. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996, 36:55-63.
4. Mlineritsch B, Mayer P, Rass C, Reiter E, Russ G, Vesenmayer G, Oberaigner W, Hausmaninger H. Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure. Onkologie 2004, 27:441-46. 10.1159/000080363, 15585973.
5. Huober J, Fett W, Nusch A, Neise M, Schmidt M, Wischnik A, Gerhardt S, Goehler T, Lück HJ, Rost A. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer 2010, 10:2. 10.1186/1471-2407-10-2, 2806246, 20047698.
6. Al-Batran SE, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I, Morack G, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 2006, 94:1615-20. 2361305, 16685267.
7. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997, 15:3185-91.
8. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1037-47. 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z, 10964334.
9. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004, 15:440-49. 10.1093/annonc/mdh097, 14998846.
10. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004, 22:3893-901. 10.1200/JCO.2004.08.157, 15459210.
11. Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart M. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 2006, 42:882-87. 10.1016/j.ejca.2005.12.011, 16520033.
12. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol 2007, 18:1159-64. 10.1093/annonc/mdl477, 17229768.
13. Vardy J, Dadasovich R, Beale P, Boyer M, Clarke SJ. Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials. BMC Cancer 2009, 9:130. 10.1186/1471-2407-9-130, 2683856, 19402889.
14. Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R, . Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006, 107:2408-16. 10.1002/cncr.22263, 17054106, Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia.
15. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007, 25:3853-8. 10.1200/JCO.2007.11.9776, 17679724.
16. Bartsch R, De Vries C, Pluschnig U, Dubsky P, Bago-Horvath Z, Gampenrieder SP, Rudas M, Mader RM, Rottenfusser A, Wiltschke C, Gnant M, Zielinski CC, Steger GG. Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. BMC Cancer 2009, 9:367. 10.1186/1471-2407-9-367, 2770076, 19835621.
17. Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, Pober M, Zielinski CC, Steger GG, . Austrian Fulvestrant Registry The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. Breast Cancer Res Treat 2009, 115:373-80. 10.1007/s10549-008-0132-0, 18661231, Austrian Fulvestrant Registry.
18. Fiegl M, Hilbe W, Auberger J, Schmid T, Auberger T, Tzankov A, Sterlacci W, Denz H, Jamnig H, Greil R. Twelve-year retrospective analysis of lung cancer--The TYROL Study: Daily routine in 1,424 patients (1995-2006). J Clin Oncol 2008, 26(15S):19063.
19. Perez AT, Domenech GH, Frankel C, Vogel CL. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience. Cancer Invest 2002, 20(Suppl 2):2-29.
20. Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006, 70:141-46. 10.1159/000093005, 16645327.
21. Sun WL, Hutarew G, Gradl J, Gratzl M, Heumader E, Denz H, Fiegl M. Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei. Memo 2009, 2:113-15.
22. Al-Batran SE, Güntner M, Pauligk C, Scholz M, Chen R, Beiss B, Stopatschinskaja S, Lerbs W, Harbeck N, Jäger E. Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials. Br J Cancer 2010, 103:1518-23. 10.1038/sj.bjc.6605961, 20978502.
23. Alba E, Ruiz-Borrego M, Margelí M, Rodríguez-Lescure A, Sánchez-Rovira P, Ruiz A, Mel-Lorenzo JR, Ramos-Vázquez M, Ribelles N, Calvo E, Casado A, Márquez A, Vicente D, García-Sáenz JA, Martín M. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 2010, 122:169-76. 10.1007/s10549-010-0860-9, 20361253.
24. Murphy CG, Khasraw M, Seidman AD. Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer. Breast Cancer Res Treat 2010, 122:177-9. 10.1007/s10549-010-0925-9, 20458530.
25. Von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, Scotte F, Lorusso D, Dummer R, Lacouture ME, Lademann J, Hauschild A. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 2008, 44:781-90. 10.1016/j.ejca.2008.01.028, 18331788.
26. Broeyer FJ, Osanto S, Ritsema van Eck HJ, van Steijn AQ, Ballieux BE, Schoemaker RC, Cohen AF, Burggraaf J. Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. J Cancer Res Clin Oncol 2008, 134:961-68. 10.1007/s00432-008-0372-8, 2515587, 18343950.